Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03123393 · ClinicalTrials.gov registry record · Phase 2
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Calithera Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT03123393 is a Phase 2 study that was terminated before completion, run by Calithera Biosciences. The registered enrollment target is 49 participants.
The verdict
NCT03123393, a Phase 2 study, was terminated before completion, sponsored by Calithera Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of TAK-659 measured by independent radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with relapsed or refractory DLBCL.
Interventions
- DRUG TAK-659
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2019-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03123393
The ClinicalTrials.gov registry entry for NCT03123393 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-659 is the first listed.
NCT03123393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03123393 about?
NCT03123393 is a clinical study titled "TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". The purpose of this study is to assess the efficacy of TAK-659 measured by independent radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with relapsed or refractory DLBCL.
What is the current status of trial NCT03123393?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2017-10-10. Estimated completion is 2019-12-17.
What interventions are being tested in trial NCT03123393?
The interventions under investigation include: TAK-659 (DRUG).
Who is sponsoring clinical trial NCT03123393?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.